reports
- GlobalData Healthcare Department
Orexigen Therapeutics Inc (OREX) - Financial and Strategic SWOT Analys...
Orexigen Therapeutics Inc (OREX) - Financial and Strategic SWOT Analysis Review Summary Orexigen Therapeutics Inc (Orexigen) is a biopharmaceutical company which develops and commercializes indications for the treatment of obesity. Its lead product, Contrave (naltrexone HCl / bupropion HCl prolonged release) is FDA approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. Contrave is also approved in Europe under the brand name My...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.